FDA Mulls Options for Regulating Next-Gen Sequencing Platforms in Clinical Diagnostics

"The goal here is to find the appropriate questions to ask and that can be answered with a reasonable amount of clarity so for future platforms that are brought to the FDA for clinical diagnostics use, we can ask the right questions," said an FDA official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories